Metagenomi Therapeutics (MGX) Share-based Compensation (2023 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly Share-based Compensation of $8.4 million for Q1 2026, up 186.89% year-over-year from $2.9 million in Q1 2025, and up 211.8% quarter-over-quarter from $2.7 million in Q4 2025.
Metagenomi Therapeutics (MGX) Share-based Compensation (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Share-based Compensation for 4 consecutive years, with $8.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 186.89% year-over-year to $8.4 million; the TTM figure through Mar 2026 stood at $8.4 million (down 40.32% YoY), while the FY2025 annual figure was $11.9 million, down 26.85% from the prior year.
- Share-based Compensation climbed to $8.4 million in Q1 2026 per MGX's latest filing, from $2.7 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $26.4 million in Q4 2023 and bottomed at $529000.0 in Q1 2023.
- Historically, Share-based Compensation has averaged $5.2 million across 4 years, with a median of $3.2 million in 2024.
- On a YoY basis, Share-based Compensation climbed as much as 855.95% in 2024 and fell as far as 87.07% in 2024.
- Metagenomi Therapeutics' Share-based Compensation stood at $26.4 million in 2023, then sank by 87.07% to $3.4 million in 2024, then slipped by 21.04% to $2.7 million in 2025, then jumped by 211.8% to $8.4 million in 2026.
- Business Quant data shows MGX's Share-based Compensation at $8.4 million in Q1 2026, $2.7 million in Q4 2025, and $3.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Metagenomi Therapeutics | 45.38 Mn | 45.38 Mn | - | 2.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.27 Mn |
| Jun 30, 2026 | 2.27 Mn |
| Mar 31, 2026 | 8.40 Mn |
| Mar 31, 2026 | 8.40 Mn |
| Dec 31, 2025 | 2.69 Mn |
| Dec 31, 2025 | 2.69 Mn |
| Sep 30, 2025 | 3.01 Mn |
| Sep 30, 2025 | 3.01 Mn |
| Jun 30, 2025 | 3.22 Mn |
| Jun 30, 2025 | 3.22 Mn |
| Mar 31, 2025 | 2.93 Mn |
| Mar 31, 2025 | 2.93 Mn |
| Dec 31, 2024 | 3.41 Mn |
| Dec 31, 2024 | 3.41 Mn |
| Sep 30, 2024 | 3.22 Mn |
| Sep 30, 2024 | 3.22 Mn |
| Jun 30, 2024 | 4.51 Mn |
| Jun 30, 2024 | 4.51 Mn |
| Mar 31, 2024 | 5.06 Mn |
| Mar 31, 2024 | 5.06 Mn |